The future prospects: dual-pathway inhibition is gaining momentum in oncology, exemplified by the combination of avutometinib (MEK/RAF inhibitor) and defactinib (FAK inhibitor), which targets both tumor signaling and the microenvironment, showing promise in KRAS-mutated cancers like LGSOC.172 Future strategies include multi-functional single agents and combinatorial regimens extended to pancreatic and triple-negative breast cancers, with MEK/FAK plus immunotherapy also under evaluation. Here, MAP2K7 is linked to triple-negative breast carcinoma.